Publikationen von Michael Werner Sereda

Berghoff, S. A.; Spieth, L.; Sun, T.; Hosang, L.; Schlaphoff, L.; Depp, C.; Düking, T.; Winchenbach, J.; Neuber, J.; Ewers, D. et al.; Scholz, P.; van der Meer, F.; Cantuti-Castelvetri, L.; Sasmita, A. O.; Meschkat, M.; Ruhwedel, T.; Möbius, W.; Sankowski, R.; Prinz, M.; Huitinga, I.; Sereda, M. W.; Odoardi, F.; Ischebeck, T.; Simons, M.; Stadelmann-Nessler, C.; Edgar, J. M.; Nave, K.-A.; Saher, G.: Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis. Nature Neuroscience 24, S. 47 - 60 (2021)

Prukop, T.; Wernick, S.; Boussicault, L.; Ewers, D.; Jäger, K.; Adam, J.; Winter, L.; Quintes, S.; Linhoff, L.; Barrantes‐Freer, A. et al.; Bartl, M.; Czesnik, D.; Zschüntzsch, J.; Schmidt, J.; Primas, G.; Laffaire, J.; Rinaudo, P.; Brureau, A.; Nabirotchkin, S.; Schwab, M. H.; Nave, K.-A.; Hajj, R.; Cohen, D.; Sereda, M. W.: Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats. Journal of Neuroscience Research 98 (10), S. 1933 - 1952 (2020)

Rudnik‐Schöneborn, S.; Thiele, S.; Walter, M. C.; Reinecke, L.; Sereda, M. W.; Schöneborn, R.; Elbracht, M.: Pregnancy outcome in Charcot–Marie–Tooth disease: results of the CMT‐NET cohort study in Germany. European Journal of Neurology 27 (8), S. 1390 - 1396 (2020)

Siems, S. B.; Jahn, O.; Eichel, M. A.; Kannaiyan, N.; Wu, L. M. N.; Sherman, D. L.; Kusch, K.; Hesse, D.; Jung, R. B.; Fledrich, R. et al.; Sereda, M. W.; Rossner, M. J.; Brophy, P. J.; Werner, H. B.: Proteome profile of peripheral myelin in healthy mice and in a neuropathy model. eLife 9, e51406 (2020)

Joseph, S.; Vingill, S.; Jahn, O.; Fledrich, R.; Werner, H. B.; Katona, I.; Möbius, W.; Mitkovski, M.; Huang, Y.; Weis, J. et al.; Sereda, M. W.; Schulz, J. B.; Nave, K.-A.; Stegmüller, J.: Myelinating glia-specific deletion of Fbxo7 in mice triggers axonal degeneration in the central nervous system together with peripheral neuropathy. The Journal of Neuroscience 39 (28), S. 5606 - 5626 (2019)

Fledrich, R.; Akkermann, D.; Schütza, V.; Abdelaal, T. A. M.; Hermes, D.; Schäffner, E.; Soto Bernardini, M. C.; Götze, T.; Klink, A.; Kusch, K. et al.; Krueger, M.; Kungl, T.; Frydrychowicz, C.; Möbius, W.; Brück, W.; Mueller, W. C.; Bechmann, I.; Sereda, M. W.; Schwab, M. H.; Nave, K.-A.; Stassart, R. M.: NRG1 type I dependent autoparacrine stimulation of Schwann cells in onion bulbs of peripheral neuropathies. Nature Communications 10, 1467 (2019)

Prukop, T.; Stenzel, J.; Wernick, S.; Kungl, T.; Mroczek, M.; Adam, J.; Ewers, D.; Nabirotchkin, S.; Nave, K.-A.; Hajj, R. et al.; Cohen, D.; Sereda, M. W.: Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PLoS One 14 (1), e0209752 (2019)

Fledrich, R.; Abdelaal, T. A. M.; Rasch, L.; Bansal, V.; Schütza, V.; Brügger, B.; Lüchtenborg, C.; Prukop, T.; Stenzel, J.; Rahman, R.U. et al.; Hermes, D.; Ewers, D.; Möbius, W.; Ruhwedel, T.; Katona, I.; Weis, J.; Klein, D.; Martini, R.; Brück, W.; Müller, W.C.; Bonn, S.; Bechmann, I.; Nave, K.-A.; Stassart, R. M.; Sereda, M. W.: Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy. Nature Communications 9, 3025 (2018)

Fledrich, R.; Mannil, M.; Leha, A.; Ehbrecht, C.; Solari, A.; Pelayo-Negro, A. L.; Berciano, J.; Schlotter-Weigel, B.; Schnizer, T. J.; Prukop, T. et al.; Garcia-Angarita, N.; Czesnik, D.; Haberlová, J.; Mazanec, R.; Paulus, W.; Beissbarth, T.; Walter, M. C.; CMT-TRIAAL; Hogrel, J.-Y.; Dubourg, O.; Schenone, A.; Baets, J.; De Jonghe, P.; Shy, M. E.; Horvath, R.; Pareyson, D.; Seeman, P.; Young, P.; Sereda, M. W.: Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. Journal of Neurology, Neurosurgery & Psychiatry 88 (11), S. 941 - 952 (2017)

Kleinecke, S.; Richert, S.; de Hoz, L.; Brügger, B.; Kungl, T.; Asadollahi, E.; Quintes, S.; Blanz, J.; McGonigal, R.; Naseri, K. et al.; Sereda, M. W.; Sachsenheimer, T.; Lüchtenborg, C.; Möbius, W.; Willison, H.; Baes, M.; Nave, K.-A.; Kassmann, C. M.: Peroxisomal dysfunctions cause lysosomal storage and axonal Kv1 channel redistribution in peripheral neuropathy. eLife 6, e23332 (2017)

Günther, R.; Balck, A.; Koch, J. C.; Nientiedt, T.; Sereda, M.; Bähr, M.; Lingor, P.; Tönges, L.: Rho kinase inhibition with Fasudil in SOD1(G93A) mouse model of Amyotrophic Lateral Sclerosis - symptomatic treatment potential after diesease onset. Frontiers in Pharmacology 8, 17 (2017)

Sociali, G.; Visigalli, D.; Prukop, T.; Cervellini, I.; Mannino, E.; Venturi, C.; Bruzzone, S.; Sereda, M. W.; Schenone, A.: Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy. Neurobiology of Disease 95 (11), S. 145 - 157 (2016)

Quintes, S.; Brinkmann, B. G.; Ebert, M.; Fröb, F.; Kungl, T.; Arlt, F. A.; Tarabykin, V.; Huylebroeck, D.; Meijer, D.; Suter, U. et al.; Wegner, M.; Sereda, M. W.; Nave, K.-A.: Zeb2 is essential for Schwann cell differentiation, myelination and nerve repair. Nature Neuroscience 19 (8), S. 1050 - 1059 (2016)

Pehlivan, D.; Beck, C. R.; Okamoto, Y.; Harel, T.; Akdemir, Z. H. C.; Jhangiani, S. N.; Withers, M. A.; Goksungur, M. T.; Carvalho, C. M. B.; Czesnik, D. et al.; Wiszniewski, W.; Muzny, D. M.; Gibbs, R. A.; Rautenstrauss, B.; Sereda, M. W.; Lupski, J. R.: The role of combined SNV and CNV burden in patients with distal symmetric polyneuropathy. Genetics in Medicine 18 (5), S. 443 - 451 (2016)

Patzig, J.; Kusch, K.; Fledrich, R.; Eichel, M. A.; Lüders, K. A.; Möbius, W.; Sereda, M. W.; Nave, K.-A.; Martini, R.; Werner, H. B.: Proteolipid protein modulates preservation of peripheral axons and premature death when myelin protein zero is lacking. Glia 64 (1), S. 155 - 174 (2016)

Epplen, D. B.; Prukop, T.; Nientiedt, T.; Albrecht, P.; Arlt, F. A.; Stassart, R. M.; Kassmann, C. M.; Methner, A.; Nave, K.-A.; Werner, H. B. et al.; Sereda, M. W.: Curcumin therapy in a Plp1 transgenic mouse model of Pelizaeus-Merzbacher disease. Annals of Clinical and Translational Neurology 2 (8), S. 787 - 796 (2015)

Ekins, S.; Litterman, N. K.; Arnold, R. J. G.; Burgess, R. W.; Freundlich, J. S.; Gray, S. J.; Higgins, J. J.; Langley, B.; Willis, D. E.; Notterpek, L. et al.; Pleasure, D.; Sereda, M. W.; Moore, A.: A brief review of recent Charcot-Marie-Tooth research and priorities. Faculty of 1000 Research 4, 53 (2015)

Chumakov, I.; Milet, A.; Cholet, N.; Primas, G.; Boucard, A.; Pereira, Y.; Graudens, E.; Mandel, J.; Laffaire, J.; Foucquier, J. et al.; Glibert, F.; Bertrand, V.; Nave, K.-A.; Sereda, M. W.; Vial, E.; Guedj, M.; Hajj, R.; Nabirotchkin, S.; Cohen, D.: Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet Journal of Rare Diseases 9 (1), 201 (2014)

Mannil, M.; Solari, A.; Leha, A.; Pelayo-Negro, A. L.; Berciano, J.; Schlotter-Weigel, B.; Walter, M. C.; Rautenstrauss, B.; Schnizer, T. J.; Schenone, A. et al.; Seeman, P.; Kadian, C.; Schreiber, O.; Angarita, N. G.; Fabrizi, G. M.; Gemignani, F.; Padua, L.; Santoro, L.; Quattrone, A.; Vita, G.; Calabrese, D.; CMT-TRIAAL/CMT-TRAUK Group; Young, P.; Laurà, M.; Haberlová, J.; Mazanec, R.; Paulus, W.; Beissbarth, T.; Shy, M. E.; Reilly, M. M.; Pareyson, D.; Sereda, M. W.: Selected items from the Charcot-Marie-Tooth (CMT) neuropathy score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders 24 (11), S. 1003 - 1017 (2014)

Avenali, L.; Narayanan, P.; Rouwette, T.; Cervellini, I.; Sereda, M.; Gomez-Varela, D.; Schmidt, M.: Annexin A2 regulates TRPA1-dependent nociception. Journal of Neuroscience 34 (44), S. 14506 - 14516 (2014)